The following studies have contributed to our Methamphetamine Dependence datasets.
Study 37 – Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder; CTN-0068
Investigator: Madhukar Trivedi Release Date: TBA View Study in Clinical Trials Network Site Study Objective: The primary objective of this study is to evaluate the efficacy of extended-release naltrexone plus bupropion as a combination pharmacotherapy for methamphetamine use disorder. Secondary objectives include assessing the safety of naltrexone plus bupropion and determining the efficacy of the combination pharmacotherapy on other substance...
Study 47 – Ketamine for Methamphetamine Use Disorder (KMD); CTN-0132
Principal Investigator: Madhukar H. Trivedi, M.D. Co-Investigators: Manish K. Jha, MBBS; Sidarth Wakhlu, M.D., Thomas Carmody, Ph.D. Release Date: TBA Objective: The primary objective of this study will be to assess preliminary efficacy, safety, and feasibility of a course of intravenous (IV) ketamine (compared with IV midazolam) as a treatment for methamphetamine use disorder. Significance/Impact: Effective management for methamphetamine use...
Study 48 – Methamphetamine and Other Substance Use Disorder Genetics in Thailand
Principal Investigator: Joel Gelernter, M.D. Co-Investigators: Rasmon Kalayasiri, M.D.; Kittipong Sanichwankul, M.D. Release Date: TBA Project Summary: Methamphetamine use disorder (MUD) is a hugely destructive public health problem that is surging worldwide, including in many parts of the US and Asia. Thailand is an optimal site for studying the genetics of MUD, owing to lower genetic and environmental heterogeneity than...